Semmax Financial Advisors Inc. Raises Position in Pfizer Inc. $PFE

Key Points

• Semmax Financial Advisors Inc. increased its stake in Pfizer by 10.4%, owning 114,160 shares valued at approximately $2.89 million.
• Pfizer updated its FY 2025 earnings guidance to 2.900-3.100 EPS, with quarterly revenue rising by 10.3% year-over-year.
• The stock's current average target price is $28.12 with a consensus "Hold" rating, as various brokerages adjust their price objectives.

Semmax Financial Advisors Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 114,160 shares of the biopharmaceutical company's stock after acquiring an additional 10,778 shares during the period. Semmax Financial Advisors Inc.'s holdings in Pfizer were worth $2,893,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Logan Capital Management Inc. grew its position in shares of Pfizer by 14.5% during the 1st quarter. Logan Capital Management Inc. now owns 602,162 shares of the biopharmaceutical company's stock valued at $15,259,000 after acquiring an additional 76,174 shares during the period. Faithward Advisors LLC grew its position in shares of Pfizer by 59.4% during the 1st quarter. Faithward Advisors LLC now owns 12,314 shares of the biopharmaceutical company's stock valued at $312,000 after acquiring an additional 4,588 shares during the period. MBB Public Markets I LLC bought a new position in shares of Pfizer during the 1st quarter valued at approximately $307,000. Ascent Group LLC grew its position in shares of Pfizer by 47.0% during the 1st quarter. Ascent Group LLC now owns 102,350 shares of the biopharmaceutical company's stock valued at $2,594,000 after acquiring an additional 32,713 shares during the period. Finally, Arete Wealth Advisors LLC grew its position in shares of Pfizer by 17.7% during the 1st quarter. Arete Wealth Advisors LLC now owns 102,164 shares of the biopharmaceutical company's stock valued at $2,589,000 after acquiring an additional 15,392 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on PFE shares. Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Bank of America raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.95 on Friday, hitting $23.91. 69,569,550 shares of the company traded hands, compared to its average volume of 44,872,492. The firm's 50-day simple moving average is $24.82 and its 200 day simple moving average is $24.32. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $135.95 billion, a P/E ratio of 12.72, a P/E/G ratio of 0.87 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer's dividend payout ratio (DPR) is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.